Prior to joining EnVivo, Kees was CEO of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery platform to advance drug candidates for cancer and inflammation. Prior to joining Bionaut, Kees spent four years at Biogen where he directed the Oncology Business Unit and, as Senior Vice President of Business Development, led all of Biogen’s deal-making efforts and portfolio management activities. Major deals he oversaw include the collaborations with Elan on Antegren (now Tysabri), with ICOS on the oral LFA-1 antagonist, and with EOS Biotechnology on breast cancer target discovery. Prior to joining Biogen in 1999, Kees held executive positions with Monsanto Life Sciences Company and was mainly involved in corporate change projects and large growth strategies in Latin America. From 1988-1995, Kees worked at Gemini Consulting where his last position was Vice President, responsible for building the pharmaceuticals practice. He began his career as a scientist on the Interferon-gamma project at Biogen in Geneva, Switzerland. He holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering. |